Azasetron for the treatment of sudden sensorineural hearing loss

Abstract

Azasetron or an analog thereof, or a pharmaceutically acceptable salt and/or solvate thereof, for treating severe or profound sudden sensorineural hearing loss (SSNHL) in a subject in need thereof. In particular, azasetron or an analog thereof, or a pharmaceutically acceptable salt and/or solvate thereof, for treating severe or profound SSNHL in a subject suffering from severe or profound SSNHL associated with (i) a hearing threshold at baseline corresponding to a pure tone audiometry (PTA) at baseline equal to or greater than 70 dB, preferably equal to or greater than 80 dB, more preferably equal to or greater than 90 dB; (ii) a hearing loss at baseline equal to or greater than 91 dB corresponding to a profound hearing loss according to the American Speech-Language-Hearing Association (ASHA) classification; (iii) a hearing loss at baseline affecting frequencies equal to or lower than 2000 Hz; and/or (iv) the presence of vertigo at baseline.

Dependencies are inferred from the claim text.